GSK has also commenced a Phase I global trial to support a registrational pathway for the therapy. The company acquired exclusive global rights from Hansoh in early 2024 to progress the clinical ...

GSK's experimental IL-5 inhibitor depemokimab ... to offer targeted and sustained suppression of a key inflammatory pathway underlying nasal polyp growth and nasal obstruction," he added.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...

Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP ...

The Trump administration's apparent vaccine skepticism and proposed tariffs on Pharma could significantly impact GSK plc's vaccine division and its overall profitability, despite CEO Walmsley's ...